---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-006746"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2022-01-11T23:59:59+00:00"
generated_at: "2026-06-27T18:57:45.515214+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroPace reports preliminary Q4 2021 revenue of $11.0M (+2% YoY); FY2021 $45.2M (+10% YoY)

## Summary
- Q4 2021 revenue ~$11.0M (+2% YoY); initial implant $8.5M (+10%), replacement $2.5M (-19%).
- FY2021 revenue ~$45.2M (+10% YoY); initial implant $33.7M (+20%), replacement $11.5M (-12%).
- 150 centers performed RNS implant in 2021, up 14% from 132 centers in 2020.
- Enrolled first patient in adolescent study to expand indications beyond current pool.
- Full Q4 and FY results expected in mid-March 2022.

## SEC filing metadata
- accession: 0001193125-22-006746
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2022-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/0001193125-22-006746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312522006746/d276070d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-006746
- JSON: https://secwatch.observer/filing/0001193125-22-006746.json
- Plain text: https://secwatch.observer/filing/0001193125-22-006746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.